Boostrix

Boostrix® packaging change for ProPharma stock

Thursday, 31 January 2013

The packaging for ProPharma supplied Boostrix® will be changing.

GSK have issued a letter to general practices outlining the changes. The appearance of the single dose packaging has already changed for privately purchased stock from Healthcare Logistics.

Funded Boostrix® in pregnancy

Wednesday, 12 December 2012

PHARMAC have extended the availability of funded Boostrix® for pregnant women between 28-38 weeks gestation from 1 January 2013.

New Zealand is in the midst of a pertussis epidemic. PHARMAC recently sought feedback on a proposal to extend funded Boostrix® for pregnant women in addition to those aged 11 years as per the National Immunisation Schedule.

Considerations and commentary around this decision are available in the  PHARMAC media release.

Capital and Coast free whooping cough boosters

Thursday, 15 November 2012

The whooping cough vaccine is available for family/whānau of infants less than one year of age who are already accessing specified immunisation services.

The vaccine, Boostrix®, is available through general practice (GPs).

The District Health Board (DHB) will pay for the vaccine. However, providers may charge the patient a small vaccine administration fee. Please ask your GP about any vaccine administration cost.

Who is eligible?

  • Only family/whānau of infants less than one year of age already receiving immunisations through the following services:
    • An outreach immunisation service
    • An open immunisation clinic
    • One of the following Very Low Cost Access primary health services:
Compass Primary Health Care Network Ora Toa PHO Well Health Trust
Waitangirua Health Centre Ora Toa - Cannons Creek Newton Union Health Service
Massey Student Services Trust Ora Toa - Takapuwahia Te Aro Health Centre
Victoria Student Health Centre Ora Toa - Mungavin Porirua Union and Community Health Service
Pacific Health Service Porirua Ora Toa - Poneke Evolve Wellington Youth Service
Hora Te Pai Health Services    

 

 

Waikato free whooping cough boosters

Friday, 14 September 2012

The whooping cough vaccine is available free for pregnant women from 20 weeks gestation and new mothers up to two weeks after delivery.

The vaccine, Boostrix®, is available through general practice and clinics within the Waikato District Hospital.

Additional information and health professional resources and standing orders are available on the Waikato District Health Board Whooping cough webpage.

Counties Manukau free whooping cough boosters

Monday, 25 June 2012

The whooping cough vaccine is available free for pregnant women from 20 weeks gestation and new mothers up to two weeks after delivery.

The vaccine, Boostrix®, is available through general practice within the Counties Manukau District:

CMDHB Resources

 IMAC resources

The booster immunisation can be given anytime from 20 weeks of pregnancy to two weeks after delivery. 

For best protection of the newborn the booster immunisation would be given by the end of the 36th week of pregnancy (ideally between 31-33 weeks): 

  • This allows time for the woman's immune system to produce protection against whooping cough, reducing the risk she will have the disease when the baby is actually delivered and for the subsequent year when the baby's risk of complications from whooping cough is highest.
  • Circulating protection against whooping cough can also pass through the placenta into the baby and provide the baby with some of their own protection against the disease for a short period of time (this varies between mothers and babies).

However, after 36 weeks of pregnancy administering the booster immunisation:

  • Will increase the woman's protection against whooping cough, reducing the risk that she will have the disease during the baby's first year of life when their risk of complications from whooping cough is highest.
  • But may not allow enough time before delivery for the woman to produce whooping cough protection and for this protection to pass through the placenta into the baby.

However, after delivery of the baby administering the booster immunisation:

  • Will increase the woman's protection against whooping cough, reducing the risk that she will have the disease during the baby's first year of life when their risk of complications from whooping cough is highest.

Babies less than one year of age, and particularly less than six months of age, have the highest risk of getting whooping cough (pertussis) and needing to be hospitalised. Reducing the risk that their mother and other household members will get whooping cough means they are less likely to get the disease too. Immunity against whooping cough decreases over time, 10-15 years after having the disease and 4-6 years after having the vaccine people can get whooping cough again. This means that it is always around and there are outbreaks every few years.

Boostrix® MUST be ordered from Healthcare Logistics for pregnant and post-partum women, whānau of new babies, carers of new babies, ECE staff and any other person who works with or is around new babies and young children.

The Boostrix® stock from ProPharma, routinely kept in the vaccine fridge for the 11 year old schedule immunisation, MUST NOT be used for any person who is not receiving the 11 year old schedule Boostrix® dose or receiving a catch up of this dose up to 16 years of age.

Vaccinators can claim the cost of the vaccine and administration by invoicing POAC.

Page updated: 7 November 2012

What is the difference between Infanrix®-hexa, Infanrix®-IPV and Boostrix® vaccines?

Answer: 

The infant vaccine Infanrix®-hexa (DTaP-IPV-HepB/Hib) protects against six diseases (diphtheria, tetanus, whooping cough, polio, hepatitis B and Haemophilus influenzae type b (Hib) disease), while Infanrix®-IPV (DTaP-IPV) protects against the first four of these diseases. The adolescent and adult vaccine Boostrix® (Tdap) boosts protection against diphtheria, tetanus and acellular pertussis (whooping cough) but is sometimes used in a primary vaccine course.

The infant and adult vaccines contain different volumes of some active ingredients, or antigens. Infanrix®-hexa and Infanrix®-IPV have a higher volume of tetanus, diphtheria and acellular pertussis antigens, which are needed to stimulate a strong immune response. Boostrix® contains smaller doses of tetanus, diphtheria and pertussis antigens, the immune response to these invaders already exists, so the vaccine is only required to "remind" the immune response about how to respond. Local site reactions to the tetanus, diphtheria and acellular pertussis vaccines increase after the fourth dose, so the smaller dose of these components also helps to avoid these reactions in adolescents.

Boostrix®

Tdap

Boostrix® is used for booster vaccination of adolescents aged 11 years and pregnant women between 28-38 weeks gestation to protect against diphtheria, tetanus and pertussis (whooping cough).
*After immunisation protection against pertussis takes up to two weeks to develop. Whilst immunisation between 38-40 weeks gestation is still safe for mother and baby later immunisation means the newborn may still be exposed to the disease by their mother on delivery and/or during the first two weeks of life. The PHARMAC decision to limit funded Boostrix® to 28-38 weeks gestation maximises the benefit of immunisation against pertussis whilst being accountable for the use of public funds. Pregnant women can choose to purchase Boostrix® privately after 38 weeks gestation or at any time after delivery.
Boostrix® is licensed for use in children 10 years of age and over and adults as a booster vaccine. Boostrix® can be used, out of licensure in children from 7 years of age and adults, for one or all three doses of a primary course of tetanus and diphtheria vaccination, so as to provide protection from pertussis (whooping cough). There is no alternative vaccine that provides protection from pertussis available in New Zealand for this age group.  
When children are younger than the age to which the vaccine is licensed, and when the vaccine is used for a primary vaccination course, use will be outside of current licensure and parents/guardians/individuals must be fully informed of this. There are not expected to be any safety concerns for use in these circumstances.

Syndicate content